Hugh McTavish
26Patents
6h-index
10Co-inventors
66Inventor score
Filing activity: Jun 20, 1997 → Mar 8, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7608439B2 | Bio-recycling of carbon dioxide emitted from power plants | Emerging Cross-Sectional Technologies | 28 | Active |
| US7309592B2 | Ethanol production from biological wastes | Emerging Cross-Sectional Technologies | 19 | Expired |
| US6673582B2 | Microbes and methods for remediation | Chemistry; Metallurgy | 10 | Expired |
| US7677993B2 | Tennis backboard | Human Necessities | 7 | Active |
| US7811982B2 | Compounds and methods for treating cancer | Chemistry; Metallurgy | 7 | Active |
| US8017102B2 | Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer | Human Necessities | 6 | Active |
| US8016700B2 | Tennis backboard | Human Necessities | 3 | Active |
| US9205065B2 | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection | Chemistry; Metallurgy | 3 | Active |
| US7919290B2 | Bio-recycling of carbon dioxide emitted from power plants | Emerging Cross-Sectional Technologies | 2 | Active |
| US8501906B2 | Compounds and methods for treating cancer | Chemistry; Metallurgy | 2 | Active |
| US10940197B2 | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection | Chemistry; Metallurgy | 1 | Active |
| US6410258B1 | Molecular hydrogen production by direct electron transfer | Chemistry; Metallurgy | 1 | Expired |
| US10245314B2 | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection | Chemistry; Metallurgy | 1 | Active |
| US11324834B2 | Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome | Human Necessities | 0 | Active |
| US8920777B2 | Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer | Human Necessities | 0 | Active |
| US7687250B2 | Ethanol production from biological wastes | Emerging Cross-Sectional Technologies | 0 | Active |
| US10744084B2 | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection | Chemistry; Metallurgy | 0 | Active |
| US10967049B2 | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12128098B2 | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection | Chemistry; Metallurgy | 0 | Active |
| US11957783B2 | Topical immunosensitizers to treat viral and fungal infections | Human Necessities | 0 | Active |
| US10391147B2 | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US6919199B2 | Microbes and methods for remediation | Chemistry; Metallurgy | 0 | Expired |
| US9801923B2 | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US7622285B2 | Ethanol production from biological wastes | Emerging Cross-Sectional Technologies | 0 | Active |
| US9011880B2 | Compounds and methods for treating cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.